ImaginAb Inc., a global biotechnology company developing 89Zr crefmirlimab berdoxam imaging agent and radiopharmaceutical therapies announces a poster presentation at AACR 2023 of an independent analysis undertaken by AstraZeneca, on data from ImaginAb’s IAB-CD8-201 ‘iCorrelate’ Phase II study.
OncoOne, a biotechnology company focused on discovering precision medicines for cancer and autoimmune diseases, announced two poster presentations highlighting new preclinical data from its oxMIF-targeting drug candidate pipeline at the upcoming American Association for Cancer Research Annual Meeting 2023, held from April 14-19, in Orlando, Florida.
SystImmune, Inc has announced that it will present data from seven preclinical programs in poster presentations at the American Association of Cancer Research meeting, which will be held in Orlando, FL, from April 14th to 19th, 2023.
Zura Bio Limited, a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, announced the appointment of Michael D. Howell, Ph.D., to the role of Chief Scientific Officer and Head of Translational Science.
Zura Bio Announces Appointment of Chief Scientific Officer Read More »
Teva Pharmaceutical Industries Ltd. announced that the U.S. Food and Drug Administration has issued a complete response letter to its partner Alvotech for the Biologics License Application for AVT02, a high-concentration biosimilar candidate for Humira®.
Complete Response Letter Received for AVT02 Biologics License Application Read More »
RELIEF THERAPEUTICS Holding SA reported its financial results for the full-year ended December 31, 2022 and provided a corporate update.
Hansa Biopharma AB will publish its interim report for January-March 2023 at 8:00 CET on April 20, 2023.
JEOL Ltd. announces launch of a new Cryogen Reclamation System for Nuclear Magnetic Resonance on April 14, 2023.
Alvotech announced that the U.S. Food and Drug Administration has issued a complete response letter for Alvotech’s Biologics License Application for AVT02, a high-concentration biosimilar candidate for Humira®.
Alvotech Provides Regulatory Update on AVT02 Biologics License Application Read More »
Nicox SA, an international ophthalmology company, announced that its exclusive Chinese partner, Ocumension Therapeutics, has submitted a New Drug Application for approval to commercialize ZERVIATE®, 0.24%, in China, for ocular itching associated with allergic conjunctivitis.
